Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis最新文献

{"title":"Mapping the landscape of hemophilia research in Brazil.","authors":"Alessandra Faustino da Conceição Bezerra, Renan Pedra de Souza","doi":"10.1097/MBC.0000000000001390","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001390","url":null,"abstract":"","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":"37 1","pages":"41-43"},"PeriodicalIF":1.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145879780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the efficacy and safety of initial high-dose romiplostim for primary immune thrombocytopenia in the acute care setting.","authors":"Grace Bringhurst, P Christopher Parish, Hang Zeng, Danielle Boselli, Joseph B Elmes, Donald C Moore, Justin R Arnall","doi":"10.1097/MBC.0000000000001397","DOIUrl":"10.1097/MBC.0000000000001397","url":null,"abstract":"<p><p>Romiplostim is a thrombopoietin receptor agonist indicated for previously treated primary immune thrombocytopenia (ITP) that leads to dose-dependent increases in platelet counts. Higher initial doses than the standard starting dose of 1 μg/kg may have the potential to lead to faster platelet responses. We conducted a single-center, retrospective, observational study to evaluate the efficacy of romiplostim dosing strategies in adult patients with primary ITP who initiated romiplostim in the acute care setting. Patients were classified into low-dose (<3 μg/kg) or high-dose (≥3 μg/kg) based on the initial weight-based dose administered. The primary outcome was time to achieve a platelet count greater than 30 × 10 9 /l. Secondary objectives included time to platelet count greater than 50 × 10 9 /l, healthcare resource utilization, thrombotic events, and bleeding incidents. Sixty-five patients were included in the study. Patients in both dosing cohorts achieved a platelet response of greater than 30 × 10 9 /l at a median of 7 days ( P  = 0.871). There were no significant differences in healthcare resource utilization or safety events between dosing cohorts. Initial high-dose romiplostim for acute ITP did not demonstrate an improvement in time to platelet response compared to initial low-dose romiplostim.</p>","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":" ","pages":"15-19"},"PeriodicalIF":1.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145484552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel FGG variant associated with hereditary hepatic fibrinogen storage disease from Adana.","authors":"Abdul Samet Ala, Talip Sayar, Serdar Ceylaner, Ali Islek, Gokhan Tumgor","doi":"10.1097/MBC.0000000000001402","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001402","url":null,"abstract":"","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":"37 1","pages":"46"},"PeriodicalIF":1.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145879819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acquired factor XIII deficiency is associated with mortality and is not linked to hypocalcemia.","authors":"Patricia Duque, Miguel López Esteban, Patricia Piñeiro, Alicia Ortiz-Lopez, Marta Moreno-Carbonell, Pilar Lancho, Alberto Calvo, Estrella Terradillos, Cristina Pascual-Izquierdo","doi":"10.1097/MBC.0000000000001400","DOIUrl":"10.1097/MBC.0000000000001400","url":null,"abstract":"<p><strong>Background: </strong>We have previously shown that factor XIII (FXIII) levels should be above 30% in an acute care setting. The aim of this analysis was to assess morbidity and mortality in a larger sample of patients with acquired FXIII deficiency, and to explore the potential underlying causes of acquired FXIII deficiency.</p><p><strong>Material and methods: </strong>We conducted a retrospective analysis of all patients diagnosed with acquired factor XIII deficiency at a large hospital over a period of 24 months (study ID: NCT04416594; http://www.clinicaltrials.gov ). We then assessed standardized clinical and outcome data.</p><p><strong>Results: </strong>We included 65 patients with FXIII activity below 70%, and a subsequent analysis included a further 104 patients (including those from our previous report). FXIII activity was significantly lower in patients who massively bled and in those admitted to the intensive care unit (ICU). Low FXIII activity was significantly associated with longer ICU stays, a high incidence of major bleeding and multiple organ dysfunction syndrome (MODS), and increased 1- and 2-year mortality. However, we found no evidence of deranged FXIII activation in this acute care setting.</p><p><strong>Conclusions: </strong>Acquired factor XIII deficiency is associated with high morbidity and mortality rates. In the setting of acquired FXIII deficiency, the level of FXIII required for haemostasis and endothelium stabilization seem to be around 40%. Activation of FXIII seems to be warranted in order to stop bleeding.</p>","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":" ","pages":"28-37"},"PeriodicalIF":1.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145644470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the antioxidant and antithrombotic potential of Tetraclinis articulata : an in-vitro investigation on human blood.","authors":"El Mahdi Razzok, Omayma El Meziouy, Sanae Baddaoui, Kaouthar Elbirgui, Naima Abda, Yassamine Bentata, Hassane Mekhfi","doi":"10.1097/MBC.0000000000001396","DOIUrl":"10.1097/MBC.0000000000001396","url":null,"abstract":"<p><p>Interactions between medicinal plants and conventional drugs represent a growing public health concern, particularly with antithrombotic medications due to increased bleeding risk. This study aimed to evaluate in vitro the antioxidant and antithrombotic properties of Tetraclinis articulata aqueous extract. Leaves were collected in Oujda, dried, crushed, and extracted by aqueous infusion. Total phenolic content was measured using the Folin-Ciocalteu method. Antioxidant activity was assessed via DPPH and ABTS assays. Antithrombotic activity was evaluated using blood from healthy donors. Platelet aggregation was measured with optical aggregometry using thrombin as the agonist. Anticoagulant effects were assessed through prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen concentration. Fibrinolytic activity was determined by a clot-lysis assay. The extract contained 70.55 μg GAE/mg of phenolics and showed strong antioxidant activity (IC50 = 20.26 ± 0.54 μg/ml for DPPH and 8.56 ± 0.93 μg/ml for ABTS). It inhibited platelet aggregation in a dose-dependent manner: 35.2% at 0.5 mg/mL, 64.1% at 1 mg/ml, and 92.18% at 2 mg/ml. The extract significantly prolonged PT and aPTT and reduced fibrinogen levels. Clot lysis reached 34.6% at 1 mg/ml. Tetraclinis articulata exhibited potent antioxidant, antiaggregant, anticoagulant, and fibrinolytic activities in vitro . These findings support its potential as a natural antithrombotic agent. However, its strong antiaggregant effect warrants caution regarding potential adverse interactions when used alongside conventional antithrombotic treatments.</p>","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":" ","pages":"7-14"},"PeriodicalIF":1.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145484522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Danazol and cost-savings in immune thrombocytopenia and in immune thrombotic thrombocytopenic purpura.","authors":"Mala Varma, Ilan Shapira, Mark Friedman, Ibrahim Nakhoul, Vamsee Torri, Jonah Shulman, Peter Kozuch, Bruce Culliney, Amit A Patel, Joseph Yoe, Vijay P Shah, Tahir Mirzoyev, Maria Machuca","doi":"10.1097/MBC.0000000000001394","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001394","url":null,"abstract":"","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":"36 8","pages":"388-390"},"PeriodicalIF":1.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145484513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indefinite anticoagulation with reduced-intensity direct oral anticoagulants in patients with splanchnic vein thrombosis. An international practice survey.","authors":"Aurélien Delluc, Marc Carrier, Mandy Lauw, Adam Cuker, Laurent Bertoletti, Jan Beyer-Westendorf, Marcello Di Nisio, Camille Simard, Guillaume Roberge, Amye Harrigan, Sudeep Shivakumar, Leslie Skeith, Walter Ageno, Nicoletta Riva","doi":"10.1097/MBC.0000000000001388","DOIUrl":"10.1097/MBC.0000000000001388","url":null,"abstract":"<p><strong>Introduction: </strong>Low-dose direct oral anticoagulants (DOACs) could be beneficial for secondary prevention of splanchnic vein thrombosis (SVT) in subgroups of patients at high risk for recurrence. In the absence of direct evidence, we aimed to identify the practice preferences of physicians managing patients with SVT in an international web-based survey.</p><p><strong>Methods and results: </strong>An anonymous questionnaire was sent via E-Mail between April and July 2023 to members of 14 national and international scientific societies. We received 236 responses of which 175 were complete responses. After an initial 3-6 months of SVT treatment, more than 80% of respondents would continue anticoagulation in the presence of cancer, myeloproliferative neoplasms, or in case of unprovoked SVT. If anticoagulation is continued, 45.8-68.6% would use reduced-intensity dosing of DOACs. In case of compensated cirrhosis or controlled inflammatory bowel disease (IBD), 54.3% and 44.4% of respondents would continue anticoagulation and 68.8% and 73.3% would opt for reduced-intensity DOAC dosing, respectively. Gastroenterologists were more likely to discontinue anticoagulation in SVT associated with cancer, controlled IBD, or unprovoked event, and more likely to continue anticoagulation in compensated cirrhosis compared to other specialists. Overall, 96% of respondents supported prospective evaluation of low-dose DOACs for the secondary prevention of SVT.</p><p><strong>Conclusion: </strong>This survey showed that physicians adapt duration and intensity of anticoagulation therapy depending on the patient's specific condition and risk factors even in the absence of high-quality evidence. Prospective evaluation is awaited.</p>","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":" ","pages":"364-370"},"PeriodicalIF":1.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145254216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between thrombophilic gene variants and thrombosis in the Iranian population: a systematic review and meta-analysis.","authors":"Seyed Mehrab Safdari, Azadeh Rezazadeh, Danial Habibi, Samin Alavi, Mahmood Shams, Ali Noroozi-Aghideh, Akbar Dorgalaleh","doi":"10.1097/MBC.0000000000001389","DOIUrl":"10.1097/MBC.0000000000001389","url":null,"abstract":"<p><p>Thrombophilia is influenced by genetic variants, such as Factor V Leiden (FVL) and the prothrombin G20210A mutation. In clinical settings, assessing numerous genetic factors can lead to diagnostic errors and unnecessary treatments. This meta-analysis examines gene variants associated with thrombosis in the Iranian population, where their role in thrombotic disorders remains underexplored. A systematic literature search was performed across PubMed, Scopus, and Web of Science, targeting case-control studies published up to July 2025. Studies were included if they evaluated thrombophilia-related polymorphisms in Iranian patients with various thrombotic conditions, such as recurrent pregnancy loss (RPL), venous thromboembolism (VTE), or deep vein thrombosis (DVT). Advanced statistical analyses, including random-effects models, fixed-effects models, and Bayesian meta-analysis, were used to compute odds ratios (ORs) and 95% confidence intervals (CIs). From 36 studies encompassing over 14 000 participants, significant associations emerged. For RPL, FVL G1691A heterozygote (OR: 1.998, 95% CI: 1.02-3.88), methylenetetrahydrofolate reductase (MTHFR) C677T heterozygote (OR: 1.77, 95% CI: 1.31-2.39), MTHFR A1298C heterozygote (OR: 3.10, 95% CI: 1.33-7.20) and homozygote (OR: 1.69, 95% CI: 1.05-2.70), prothrombin G20210A heterozygote (OR: 2.435, 95% CI: 1.09-5.39) and homozygote (OR: 0.487, 95% CI: 0.40-0.58), plasminogen activator inhibitor-1 (PAI-1) polymorphisms, factor V (FV) A4070G, FV 5279A/G, factor XIII (FXIII) Val34Leu, and integrin subunit beta-3 (ITGB3)1565T/C were linked to elevated RPL risk. Additionally, FVL G1691A heterozygote (OR: 5.25, 95% CI: 2.39-11.54) was associated with higher VTE risk, while MTHFR C677T heterozygote (OR: 1.404, 95% CI: 1.030-1.914) increased DVT risk. These ethnicity-specific findings highlight critical genetic risk factors for thrombotic disorders in Iranians, potentially guiding precise diagnostics and personalized interventions.</p>","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":" ","pages":"349-363"},"PeriodicalIF":1.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145276988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human plasma-derived plasminogen replacement in type 1 plasminogen deficiency: a pediatric case with multisystemic manifestation.","authors":"Deniz Koçak Göl, Veysel Gök, Ebru Yilmaz, Ekrem Ünal, Musa Karakükcü, Tülin Tiraje Celkan, Alper Özcan","doi":"10.1097/MBC.0000000000001391","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001391","url":null,"abstract":"","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":"36 8","pages":"386-388"},"PeriodicalIF":1.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145484587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endotoxemia-induced protein C surge protects mice against venous thrombosis based on transient lowering of natural anticoagulants.","authors":"Marco Heestermans, Victorine Maillot, Charles-Antoine Arthaud, Amelie Prier, Marie-Ange Eyraud, Laurent Bertoletti, Anne-Claire Duchez, Hind Hamzeh-Cognasse, Fabrice Cognasse","doi":"10.1097/MBC.0000000000001392","DOIUrl":"10.1097/MBC.0000000000001392","url":null,"abstract":"<p><p>Immunothrombosis is the process by which inflammatory stimuli promote coagulation and thrombus formation. Bacterial sepsis is a well established risk factor for venous thrombosis, and numerous experimental studies have shown that sepsis indeed enhances thrombotic responses. In this study, we aimed to investigate the impact of endotoxemia - induced by either lipopolysaccharides or α-toxin - on venous thrombosis development in mice. Venous thrombosis was induced using a model based on siRNA-mediated transient inhibition of the natural anticoagulants - protein C (PC) and anti-thrombin (AT). Unexpectedly, endotoxemia attenuated rather than promoted venous thrombus formation. This counterintuitive finding appears to be explained by a transient increase in circulating protein C levels following endotoxemia. As our venous thrombosis mouse model strongly depends on the level of reduced protein C activity, this endotoxemia-induced elevation interfered with the intended prothrombotic conditions and compromised comparability between experimental groups. These results highlight the context-dependent effects of bacterial sepsis on venous thrombosis and underscore the importance of rigorous model validation in (immuno)thrombosis research.</p>","PeriodicalId":520571,"journal":{"name":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","volume":" ","pages":"381-385"},"PeriodicalIF":1.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145351251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}